Teva Pharmaceutical Industries Limited (TEVA)
USD 21.2
(1.53%)
USD 21.2
(1.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -559 Million USD | 76.24% |
| 2022 | -2.35 Billion USD | -664.27% |
| 2021 | 417 Million USD | 110.45% |
| 2020 | -3.99 Billion USD | -299.4% |
| 2019 | -999 Million USD | 53.53% |
| 2018 | -2.15 Billion USD | 86.78% |
| 2017 | -16.26 Billion USD | -5043.77% |
| 2016 | 329 Million USD | -79.28% |
| 2015 | 1.58 Billion USD | -48.02% |
| 2014 | 3.05 Billion USD | 140.74% |
| 2013 | 1.26 Billion USD | -35.35% |
| 2012 | 1.96 Billion USD | -28.85% |
| 2011 | 2.75 Billion USD | -17.17% |
| 2010 | 3.33 Billion USD | 66.55% |
| 2009 | 2 Billion USD | 214.96% |
| 2008 | 635 Million USD | -67.47% |
| 2007 | 1.95 Billion USD | 257.51% |
| 2006 | 546 Million USD | -49.08% |
| 2005 | 1.07 Billion USD | 223.18% |
| 2004 | 331.8 Million USD | -51.98% |
| 2003 | 691 Million USD | 68.41% |
| 2002 | 410.3 Million USD | 47.48% |
| 2001 | 278.21 Million USD | 87.45% |
| 2000 | 148.41 Million USD | 25.96% |
| 1999 | 117.83 Million USD | 71.27% |
| 1998 | 68.8 Million USD | -32.22% |
| 1997 | 101.5 Million USD | 38.28% |
| 1996 | 73.4 Million USD | -8.02% |
| 1995 | 79.8 Million USD | 11.45% |
| 1994 | 71.6 Million USD | 24.52% |
| 1993 | 57.5 Million USD | 76.38% |
| 1992 | 32.6 Million USD | 37.55% |
| 1991 | 23.7 Million USD | 13.94% |
| 1990 | 20.8 Million USD | 23.08% |
| 1989 | 16.9 Million USD | 40.83% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -139 Million USD | -132.4% |
| 2024 Q2 | -845 Million USD | -507.91% |
| 2023 Q2 | -863 Million USD | -320.98% |
| 2023 Q1 | -205 Million USD | 83.21% |
| 2023 FY | -559 Million USD | 76.24% |
| 2023 Q4 | 429 Million USD | 436.25% |
| 2023 Q3 | 80 Million USD | 109.27% |
| 2022 Q3 | 56 Million USD | 124.14% |
| 2022 Q1 | -955 Million USD | -500.63% |
| 2022 FY | -2.35 Billion USD | -664.27% |
| 2022 Q2 | -232 Million USD | 75.71% |
| 2022 Q4 | -1.22 Billion USD | -2280.36% |
| 2021 Q3 | 292 Million USD | 41.06% |
| 2021 FY | 417 Million USD | 110.45% |
| 2021 Q2 | 207 Million USD | 168.83% |
| 2021 Q4 | -159 Million USD | -154.45% |
| 2021 Q1 | 77 Million USD | -48.67% |
| 2020 FY | -3.99 Billion USD | -299.4% |
| 2020 Q3 | -4.34 Billion USD | -3206.43% |
| 2020 Q4 | 150 Million USD | 103.45% |
| 2020 Q2 | 140 Million USD | 102.9% |
| 2020 Q1 | 69 Million USD | -36.7% |
| 2019 Q2 | -689 Million USD | -556.19% |
| 2019 FY | -999 Million USD | 53.53% |
| 2019 Q1 | -105 Million USD | 96.36% |
| 2019 Q3 | -314 Million USD | 54.43% |
| 2019 Q4 | 109 Million USD | 134.71% |
| 2018 FY | -2.15 Billion USD | 86.78% |
| 2018 Q1 | 1.05 Billion USD | 109.15% |
| 2018 Q2 | -176 Million USD | -116.68% |
| 2018 Q4 | -2.88 Billion USD | -1287.5% |
| 2018 Q3 | -208 Million USD | -18.18% |
| 2017 Q2 | -5.97 Billion USD | -1129.31% |
| 2017 Q4 | -11.53 Billion USD | -2276.42% |
| 2017 Q3 | 530 Million USD | 108.88% |
| 2017 FY | -16.26 Billion USD | -5043.77% |
| 2017 Q1 | 580 Million USD | 159.61% |
| 2016 FY | 329 Million USD | -79.28% |
| 2016 Q1 | 570 Million USD | 14.0% |
| 2016 Q2 | 254 Million USD | -55.44% |
| 2016 Q3 | 348 Million USD | 37.01% |
| 2016 Q4 | -973 Million USD | -379.6% |
| 2015 Q4 | 500 Million USD | 385.44% |
| 2015 FY | 1.58 Billion USD | -48.02% |
| 2015 Q3 | 103 Million USD | -80.89% |
| 2015 Q2 | 539 Million USD | 20.85% |
| 2015 Q1 | 446 Million USD | -35.08% |
| 2014 Q3 | 876 Million USD | 17.11% |
| 2014 FY | 3.05 Billion USD | 140.74% |
| 2014 Q1 | 744 Million USD | 95.79% |
| 2014 Q2 | 748 Million USD | 0.54% |
| 2014 Q4 | 687 Million USD | -21.58% |
| 2013 Q3 | 711 Million USD | 257.3% |
| 2013 FY | 1.26 Billion USD | -35.35% |
| 2013 Q1 | 630 Million USD | 96.88% |
| 2013 Q2 | -452 Million USD | -171.75% |
| 2013 Q4 | 380 Million USD | -46.55% |
| 2012 Q1 | 859 Million USD | 69.76% |
| 2012 Q4 | 320 Million USD | 505.06% |
| 2012 Q3 | -79 Million USD | -109.15% |
| 2012 Q2 | 863 Million USD | 0.47% |
| 2012 FY | 1.96 Billion USD | -28.85% |
| 2011 FY | 2.75 Billion USD | -17.17% |
| 2011 Q4 | 506 Million USD | -44.76% |
| 2011 Q1 | 761 Million USD | -1.3% |
| 2011 Q2 | 576 Million USD | -24.31% |
| 2011 Q3 | 916 Million USD | 59.03% |
| 2010 Q1 | 713 Million USD | 88.13% |
| 2010 FY | 3.33 Billion USD | 66.55% |
| 2010 Q4 | 771 Million USD | -26.57% |
| 2010 Q3 | 1.05 Billion USD | 31.74% |
| 2010 Q2 | 797 Million USD | 11.78% |
| 2009 Q2 | 521 Million USD | 15.52% |
| 2009 Q1 | 451 Million USD | 165.55% |
| 2009 FY | 2 Billion USD | 214.96% |
| 2009 Q3 | 649 Million USD | 24.57% |
| 2009 Q4 | 379 Million USD | -41.6% |
| 2008 Q2 | 539 Million USD | 266.67% |
| 2008 Q4 | -688 Million USD | -208.01% |
| 2008 FY | 635 Million USD | -67.47% |
| 2008 Q1 | 147 Million USD | -74.21% |
| 2008 Q3 | 637 Million USD | 18.18% |
| 2007 Q4 | 570 Million USD | 8.57% |
| 2007 Q1 | 342 Million USD | -25.64% |
| 2007 FY | 1.95 Billion USD | 257.51% |
| 2007 Q2 | 515 Million USD | 50.58% |
| 2007 Q3 | 525 Million USD | 1.94% |
| 2006 Q3 | 606.4 Million USD | 24.16% |
| 2006 Q1 | -1 Billion USD | -430.83% |
| 2006 FY | 546 Million USD | -49.08% |
| 2006 Q4 | 459.9 Million USD | -24.16% |
| 2006 Q2 | 488.4 Million USD | 148.42% |
| 2005 Q1 | 259.1 Million USD | -7.07% |
| 2005 Q4 | 304.9 Million USD | 14.15% |
| 2005 Q3 | 267.1 Million USD | 10.74% |
| 2005 Q2 | 241.2 Million USD | -6.91% |
| 2005 FY | 1.07 Billion USD | 223.18% |
| 2004 Q2 | 229.5 Million USD | 153.62% |
| 2004 FY | 331.8 Million USD | -51.98% |
| 2004 Q4 | 278.8 Million USD | 10.85% |
| 2004 Q3 | 251.5 Million USD | 9.59% |
| 2004 Q1 | -428 Million USD | -329.74% |
| 2003 Q1 | 137.7 Million USD | 0.88% |
| 2003 Q4 | 186.3 Million USD | 18.97% |
| 2003 FY | 691 Million USD | 68.41% |
| 2003 Q3 | 156.6 Million USD | -25.57% |
| 2003 Q2 | 210.4 Million USD | 52.8% |
| 2002 Q3 | 96.3 Million USD | 4.79% |
| 2002 Q2 | 91.9 Million USD | 7.36% |
| 2002 Q4 | 136.5 Million USD | 41.74% |
| 2002 Q1 | 85.6 Million USD | 7.52% |
| 2002 FY | 410.3 Million USD | 47.48% |
| 2001 Q1 | 54.75 Million USD | -0.36% |
| 2001 Q3 | 79.4 Million USD | 23.2% |
| 2001 Q2 | 64.44 Million USD | 17.71% |
| 2001 FY | 278.21 Million USD | 87.45% |
| 2001 Q4 | 79.61 Million USD | 0.27% |
| 2000 Q1 | 37.86 Million USD | -5.42% |
| 2000 FY | 148.41 Million USD | 25.96% |
| 2000 Q3 | 46.6 Million USD | 418.21% |
| 2000 Q4 | 54.95 Million USD | 17.9% |
| 2000 Q2 | 8.99 Million USD | -76.25% |
| 1999 Q2 | 31.1 Million USD | 9.89% |
| 1999 Q1 | 28.3 Million USD | 1921.43% |
| 1999 Q4 | 40.03 Million USD | 117.57% |
| 1999 FY | 117.83 Million USD | 71.27% |
| 1999 Q3 | 18.4 Million USD | -40.84% |
| 1998 Q1 | 25.1 Million USD | 8266.67% |
| 1998 FY | 68.8 Million USD | -32.22% |
| 1998 Q2 | 17.1 Million USD | -31.87% |
| 1998 Q3 | 25.3 Million USD | 47.95% |
| 1998 Q4 | 1.4 Million USD | -94.47% |
| 1997 Q2 | 34 Million USD | 7.94% |
| 1997 FY | 101.5 Million USD | 38.28% |
| 1997 Q3 | 35.8 Million USD | 5.29% |
| 1997 Q4 | 300 Thousand USD | -99.16% |
| 1997 Q1 | 31.5 Million USD | 4.3% |
| 1996 Q4 | 30.2 Million USD | 26.36% |
| 1996 Q3 | 23.9 Million USD | 896.67% |
| 1996 Q2 | -3 Million USD | -113.45% |
| 1996 Q1 | 22.3 Million USD | 12.63% |
| 1996 FY | 73.4 Million USD | -8.02% |
| 1995 Q1 | 18.9 Million USD | 0.0% |
| 1995 Q3 | 21.6 Million USD | 10.77% |
| 1995 Q2 | 19.5 Million USD | 3.17% |
| 1995 FY | 79.8 Million USD | 11.45% |
| 1995 Q4 | 19.8 Million USD | -8.33% |
| 1994 Q1 | 17.1 Million USD | 5.56% |
| 1994 FY | 71.6 Million USD | 24.52% |
| 1994 Q4 | 18.9 Million USD | 8.0% |
| 1994 Q3 | 17.5 Million USD | -3.85% |
| 1994 Q2 | 18.2 Million USD | 6.43% |
| 1993 Q4 | 16.2 Million USD | 16.55% |
| 1993 Q3 | 13.9 Million USD | 0.0% |
| 1993 Q1 | 13.5 Million USD | 17.39% |
| 1993 FY | 57.5 Million USD | 76.38% |
| 1993 Q2 | 13.9 Million USD | 2.96% |
| 1992 Q4 | 11.5 Million USD | 71.64% |
| 1992 Q2 | 7 Million USD | -9.09% |
| 1992 Q1 | 7.7 Million USD | 0.0% |
| 1992 Q3 | 6.7 Million USD | -4.29% |
| 1992 FY | 32.6 Million USD | 37.55% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 FY | 23.7 Million USD | 13.94% |
| 1990 FY | 20.8 Million USD | 23.08% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 FY | 16.9 Million USD | 40.83% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | -83.99 Million USD | -565.532% |
| Bausch Health Companies Inc. | -592 Million USD | 5.574% |
| Catalent, Inc. | -1.04 Billion USD | 46.405% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 26.496% |
| Elanco Animal Health Incorporated | -1.23 Billion USD | 54.59% |
| Perrigo Company plc | -12.7 Million USD | -4301.575% |
| Zoetis Inc. | 2.34 Billion USD | 123.848% |